Media
Hua Medicine Recognized as a "Honored Enterprise in National Adverse Drug Reaction Monitoring and Evaluation for 2024"
February 26, 2025 – Shanghai, Chinai
Recently, the National Adverse Drug Reaction Monitoring Center issued the "Notice on Honoring the Units for National Adverse Drug Reaction Monitoring and Evaluation in 2024". Hua Medicine has been listed on the list of "Honored Enterprise in Pharmaceuticals, Medical Devices and Cosmetics for 2024", because of its outstanding performance in fulfilling the principal responsibility, standing out as the only pharmaceutical company in Shanghai to receive this honor.
The selection entailed recommendations from provincial-level adverse drug reaction monitoring institutions, followed by a comprehensive appraisal by the National Adverse Drug Reaction Monitoring Center. The commendation acknowledges outstanding medical institutions, enterprises in pharmaceuticals, medical devices and cosmetics, and grassroots monitoring agencies in adverse reaction monitoring and evaluation in 2024.
Since its establishment, Hua Medicine has committed to its operational tenet of “high standards, high quality, and creating high value”. The company has systematically developed an adverse drug reaction/event monitoring and regulatory framework, strictly adhered to the relevant regulations set by the National Medical Products Administration, and established a standardized drug safety monitoring and evaluation system to effectively fulfill its primary responsibility for drug safety.
Hua Medicine’s globally first-in-class drug, glucokinase activator HuaTangNing (华堂宁®) (dorzagliatin tablets), was approved for marketing in September 2022 and was included in the National Reimbursement Drug List by the end of 2023. Since the launch of this drug, Hua Medicine has diligently fulfilled its responsibility for adverse drug reaction/event reporting, conducted prompt and professional analysis of each adverse drug reaction/event report, leveraging the expertise of internal and external experts from its safety committee to make scientific judgments. Concurrently, it has actively carried out post-marketing safety studies to enhance the capacity and level of ensuring the safety of clinical drug use.
Looking ahead, Hua Medicine will continue to advance its pharmacovigilance system, reinforce its sense of social responsibility and mission, and make even more significant contributions to safeguarding public health.
About Hua Medicine
Hua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (华堂宁®) (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing (华堂宁®) was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.
For more information
Hua Medicine
Website: www.ksxianqing.com
Investors
E-mail: ir@ksxianqing.com
Media
E-mail: pr@ksxianqing.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
